About Non alcoholic steatohepatitis (NASH) – Pipeline Analysis
“Non alcoholic steatohepatitis (NASH)Pipeline Analysis” gives comprehensive insight on the various drugs being developed for the treatment of NASH . The report covers all the drugs being developed in various phases (Discovery, Pre clinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Re combinant proteins and RNA-based therapeutics, but excludes Off-label, symptom relief drugs, generic combinations. The report also covers hot targets in research for NASH treatments and disease progression bio markers.
Request For Sample Report @ https://www.reportsandmarkets.com/sample-request/859501-nonalcoholicsteatohepatitis-nash-pipeline-analysis
This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Non alcoholic steatohepatitis (NASH)Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space.
NASH is associated with fatty liver, hepatic inflammation, hepatocyte injury and fibro genesis and may worsen into fibro sisorcirrhosis, liver failure and rarely into liver cancer. Currently, there are no approved drugs for NASH by U.S. Food and Drug Administration(FDA) and there a high unmet clinical need.NASH,if untreated can progress to liver-destroying cirrhosis and potentially cancer.
Majority of the NASH pipeline drugs are from specialized small to mid pharmaceutical & biotech companies. As some of the candidates are nearing key R&D milestones, there is a huge competition among large pharmaceutical and biotech companies to acquire these assets. Gilead ’s acquisition of Phenex FXR program & Boehringer’s acquisition of NASH clinical asset from Phar-max is supports this trend. Diagnosis of NASH still requires histological confirmation and there is a great demand for specific non-invasive diagnosis for distinguishing NASH fro mother liver diseases. Therefore , there is a need to develop better diagnostic and therapeutic strategies for patients with NASH.
Request For Discount: https://www.reportsandmarkets.com/check-discount/859501-nonalcoholicsteatohepatitis-nash-pipeline-analysis
There is a tremendous opportunity for upcoming therapies specific to NASH such as MAbs, RNA-based therapies & Recombinant proteins. These modalities may provide Anti-fibrosis,Anti-inflammatory and metabolic benefits.
REPORT DESCRIPTION INTRODUCTION
• Causes & Symptoms
• Unmet needs
• Current therapies
HOT TARGETS, MECHANISMS & THERAPIES
• Novel Disease mechanisms & therapies
• Leading & hot targets of NASH
• Novel targets of NASH
• NASH biomarkers • Genes involved in NASH
• Forecasting model
• Market dynamics
• Market sizing
• NASH Deals
• Development stage
• Leading players
• Therapeutic segmentation
• Target analysis
• Innovative approaches
• Competitive landscape Large molecules
• Competitive landscape RNA-BASED THERAPY
• Competitive landscape RECOMBINANT PROTEINS
• Competitive landscape ANTIBODIES
• Competitive landscape LARGE MOLECULES (UNSPECIFIED)
NASH DRUG ANALYSIS BASED ON MECHANISM
• Company Profiles
• Overview, Pipeline & Deals
About Reports and Markets
Reports and Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.
Manager – Partner Relations & International Marketing
Ph: +1-214-377-1121 (US)